1. Stirpe, P., et al., Constipation: an emerging risk factor for Parkinson’s disease? Eur J Neurol, 2016. 23(11): p. 1606-1613. Länk (open access)
2. Driver-Dunckley, E., et al., Olfactory dysfunction in incidental Lewy body disease and Parkinson’s disease. Parkinsonism Relat Disord, 2014. 20(11): p. 1260-2. Länk (open access)
3. Howell, M.J. and C.H. Schenck, Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Disease. JAMA Neurol, 2015. 72(6): p. 707-12. Länk (inte open access), alternativ källa med PDF hittas via Google Scholar)
4. Berg, D., et al., MDS research criteria for prodromal Parkinson’s disease. Mov Disord, 2015. 30(12): p. 1600-11. Länk, alternativ källa med PDF hittas via Google Scholar)
5. Chadchankar, H., et al., Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein. Brain Res, 2011. 1382: p. 37-44., Länk (inte open access), alternativ källa med PDF hittas via Google Scholar)
6. Burre, J., et al., Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science, 2010. 329(5999): p. 1663-7. Länk (open access)
7. Näsström, T., et al., The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers. Biochem Biophys Res Commun, 2009. 378(4): p. 872-6. Länk (inte open access)
8. Tokuda, T., et al., Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology, 2010. 75(20): p. 1766-72. Länk (open access)
9. Hansson, O., et al., Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther, 2014. 6(3): p. 25. Länk (open access)
10. Donadio, V., et al., Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology, 2014. 82(15): p. 1362-9.
11. Donadio, V., et al., Skin nerve misfolded alpha-synuclein in pure autonomic failure and Parkinson disease. Ann Neurol, 2016. 79(2): p. 306-16.
12. Rodriguez-Leyva, I., et al., alpha-Synuclein inclusions in the skin of Parkinson’s disease and parkinsonism. Ann Clin Transl Neurol, 2014. 1(7): p. 471-8.
13. Sharma, S.K., Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology, 2014. 83(17): p. 1582.
14. Zange, L., et al., Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson’s disease from multiple system atrophy. Brain, 2015. 138(Pt 8): p. 2310-21.
15. Appel, L., et al., Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. J Nucl Med, 2015. 56(2): p. 234-42.
16. Fagerqvist, T., et al., Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation. J Neurochem, 2013. 126(1): p. 131-44.